John Niederhuber, MD is Executive Vice President and CEO of Inova Translational Medicine Institute and Inova Health System and co-director of the Johns Hopkins Clinical Research Network. Dr. Niederhuber brings a lifetime of medical knowledge, large organization management experience and vision to Inova, including his most recent tenure as director of the National Cancer Institute (NCI). A nationally renowned surgeon and researcher, he has dedicated his four-decade career to the treatment and study of cancer. He has served as professor, cancer center director, National Cancer Advisory Board chair, external advisor to NCI, grant reviewer, and laboratory investigator supported by NCI and National Institutes of Health.
Dr. Niederhuber previously served as NCI’s chief operating officer and deputy director for translational and clinical sciences and chair of the National Cancer Advisory Board (NCAB). He remains involved in research at his laboratory on the National Institutes of Health (NIH) campus. As a surgeon, Dr. Niederhuber’s clinical emphasis is on gastrointestinal cancer, hepatobiliary—liver, bile duct, and gallbladder—and breast cancers. He is recognized for his pioneering work in hepatic artery infusion chemotherapy and was the first to demonstrate the feasibility of totally implantable vascular access devices.
Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Science and has received numerous honors and awards. He is co-author of Abeloff’s Clinical Oncology, 6th Edition.
Related Authors: James O. Armitage, MD; Michael B. Kastan, MD, PhD; W. Gillies McKenna, MD, PhD